Supernus Pharmaceuticals (FRA:S49) Total Equity: €931.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S49 Supernus Pharmaceuticals Inc FRA:S49
87 GF Score
Price €39.40
GF Value €36.31
Valuation Fairly Valued
View Full Analysis

What is Supernus Pharmaceuticals Total Equity?

Supernus Pharmaceuticals FRA:S49 -2.96% 87 Total Equity is €931.4 Mil as of Mar. 2026. GuruFocus rates FRA:S49 with a GF Score™ of 87/100 and a GF Value™ of €36.31 (Fairly Valued).

Supernus Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was €931.4 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Supernus Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Total Equity Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 722.03 836.58 845.03 989.13 906.70

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 953.40 922.40 894.32 906.70 931.44
FRA:S49
87GF Score
Supernus Pharmaceuticals Inc FRA:S49
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Supernus Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1240.561-333.858
=906.7

Supernus Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1298.127-366.691
=931.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €931.4 Mil mean?
Supernus Pharmaceuticals (FRA:S49) has a Total Equity of €931.4 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Total Equity too high?
Supernus Pharmaceuticals' current Total Equity is €931.4 Mil. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Total Equity compare to RGC and BCRX?
Supernus Pharmaceuticals' Total Equity of €931.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Total Equity is €931.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (FRA:S49) is currently considered Fairly Valued. The stock's GF Value™ is €36.31, compared to a current price of €39.40 — trading 8.5% above its estimated fair value. The current Total Equity is €931.4 Mil. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Supernus Pharmaceuticals (FRA:S49), the current Total Equity is €931.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (FRA:S49) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of €39.40 is trading 8.5% above its estimated GF Value™ of €36.31. GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:S49:

  • Total Equity: €931.4 Mil
  • GF Value™: €36.31 vs. price of €39.40 (8.5% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the FRA:S49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USA0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for FRA:S49

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.40
Price
€36.31
GF Value